Results 41 to 50 of about 22,921 (208)

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts [PDF]

, 2017
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
AM Zeidan, AO Soriano, BD Cheson, BD Cheson, CJ Clopper, D Merkel, DJ DeAngelo, E Raffoux, G Garcia-Manero, G Garcia-Manero, G Garcia-Manero, H Dombret, H Khan, J Babb, JP Issa, JP Issa, JP Laubach, L Maurillo, L Pleyer, M Kirschbaum, M Lubbert, Mikkael A. Sekeres, P Atadja, P Fenaux, P Fenaux, P Maslak, P Tan, PG Richardson, SD Gore, SD Nimer, T Prebet, TE Fandy, W Blum, W Fiskus, Y Ofran, YG Lee   +35 more
core   +2 more sources

Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha, Bishwas Mandal, Vishal Mandal, Asis Shrestha, Amir Babu Shrestha   +4 more
wiley   +1 more source

Mutant NPM1 in Acute Myeloid Leukemia Initiation and Maintenance

Aging and Cancer, EarlyView.
NPM1 mutations drive acute myeloid leukemia by acting as neomorphic transcriptional regulators that cooperate with Menin–MLL and XPO1 to sustain HOX/MEIS1 expression and block differentiation. Targeting these mutant‐specific transcriptional dependencies provides a rational therapeutic strategy for NPM1‐mutated AML.
Yanan Jiang, Zhong Fan, Runmeng Liu, Xiaotian Zhang   +3 more
wiley   +1 more source

Azacitidine induced lung injury: report and contemporary discussion on diagnosis and management

Frontiers in Oncology
Azacitidine, a hypomethylating agent, has caused a paradigm shift in the outcomes of patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) who are not eligible for stem cell transplantation, particularly in combination with BCL2 ...
Ruah Alyamany, Ahmed Alnughmush, Malak Almutlaq, Mohammed Alyamany, Mansour Alfayez   +4 more
doaj   +1 more source

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease [PDF]

, 2017
Azacitidine (Aza) is first-line treatment for patients with high-risk myelodysplastic syndromes (MDS), although its precise mechanism of action is unknown. We performed the first study to globally evaluate the epigenetic effects of Aza on MDS bone marrow
Abdulkadir, Hani, Ben Azenkoud, Asmaa, Corddedu, Lina, De Paepe, Ayla, Einarsdottir, Elisabet, Ekwall, Karl, Grovdal, Michael, Hellstrom-Lindberg, Eva, Jansson, Monika, Karimi, Mohsen, Katayama, Shintaro, Kere, Juha, Krjutskov, Kaarel, Lehmann, Soren, Lennartsson, Andreas, Marabita, Francesco, Tobiasson, Magnus, Ungerstedt, Johanna   +17 more
core   +1 more source

Understanding and Overcoming Antibody‐Drug Conjugate Resistance: Biological Mechanisms and Emerging Analytical Frameworks in Breast Cancer

Advanced Science, EarlyView.
Antibody–drug conjugates (ADCs) transform breast cancer therapy, yet resistance limits their durability. Emerging evidence reveals that ADC failure is not solely tumor‐intrinsic but shaped by dynamic tumor–microenvironment interactions that alter drug delivery, processing, and response.
Minji Seo, Jangsoon Lee, Naoto T. Ueno
wiley   +1 more source

Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet’s-like disease accompanied with myelodysplastic syndrome involving trisomy 8

Immunological Medicine, 2019
Myelodysplastic syndromes (MDSs) are a group of myeloid neoplasms characterized by blood cell deformation and dysfunction, and MDS with trisomy 8 is closely linked with intestinal Behçet’s-like diseases.
Nahoko Tanaka, Hirotake Sakuraba, Hiroto Hiraga, Ko Mayama, Hidezumi Kikuchi, Dai Kishida, Yui Akemoto, Keisuke Hasui, Shinji Ota, Rina Watanabe, Yasuhisa Murai, Takato Maeda, Kosuke Kamata, Tetsuya Tatsuta, Manabu Sawaya, Daisuke Chinda, Tatsuya Mikami, Kazufumi Yamagata, Yoh Ishiguro, Masanori Tanaka, Shinsaku Fukuda   +20 more
doaj   +1 more source

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial) [PDF]

, 2017
Maintenance therapy after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) is conceptually attractive to prevent relapse, but has been hampered by the limited number of suitable ...
AC West, AM Brunner, C Craddock, DJ DeAngelo, DJ DeAngelo, EM Ocio, F Giles, JF San-Miguel, JJ Cornelissen, JM Middeke, KJ Falkenberg, R Tao, SM Devine, SW Choi, WW Hancock   +14 more
core   +1 more source

Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition

Advanced Science, EarlyView.
The authors engineer colorectal cancer cells with reduced redundancy of UHRF1 and DNMT1, key DNA methylation maintenance factors, lowering the maintenance threshold and sensitizing cells to inhibition. They develop reporter assays driven by endogenous tumor‐suppressor gene promoters with enhanced sensitivity and dynamic range to demethylating drugs ...
Cuicui Xia, Ying Cui, Jiongliang Wang, Wenjing Bai, Danyang Wang, Yao Chen, Huahui Guo, Liangyi Zong, Bing Qin, Xintong Cai, Jie Wang, Jing Huang, Scott B. Rothbart, Zufeng Guo, Stephen B. Baylin, Xiangqian Kong   +15 more
wiley   +1 more source

Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia

Hematology/Oncology and Stem Cell Therapy, 2023
Objective/Background: Allogeneic hematopoietic stem cell transplant (HSCT) is the potential curative modality for poor- risk acute myeloid leukemia (AML), relapse remains the main reason for transplant failure.
Amany R. Keruakous, Jennifer Holter-Chakrabarty, Sarah A. Schmidt, Mohamad O. Khawandanah, George Selby, Carrie Yuen   +5 more
doaj   +1 more source